.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Accenture
Fuji
Novartis
Express Scripts
Merck
Farmers Insurance
Covington
Healthtrust
McKinsey

Generated: July 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 077171

« Back to Dashboard
NDA 077171 describes CLONAZEPAM, which is a drug marketed by Teva, Sun Pharm Inds Inc, Sandoz, Mylan Pharms Inc, Accord Hlthcare, Mylan, Prinston Inc, Watson Labs, Apotex Inc, Actavis Elizabeth, Par Pharm, and Barr, and is included in fifteen NDAs. It is available from forty-four suppliers. Additional details are available on the CLONAZEPAM profile page.

The generic ingredient in CLONAZEPAM is clonazepam. There are ten drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

Summary for NDA: 077171

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 077171

Ingredient-typeBenzodiazepines

Suppliers and Packaging for NDA: 077171

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLONAZEPAM
clonazepam
TABLET, ORALLY DISINTEGRATING;ORAL 077171 ANDA Par Pharmaceutical, Inc. 49884-306 49884-306-02 60 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (49884-306-02)
CLONAZEPAM
clonazepam
TABLET, ORALLY DISINTEGRATING;ORAL 077171 ANDA Par Pharmaceutical, Inc. 49884-307 49884-307-02 60 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (49884-307-02)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.125MG
Approval Date:Aug 3, 2005TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.25MG
Approval Date:Aug 3, 2005TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.5MG
Approval Date:Aug 3, 2005TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Medtronic
Express Scripts
Merck
Fish and Richardson
US Department of Justice
QuintilesIMS
Cantor Fitzgerald
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot